Bench to Bedside: Multiple Sclerosis and Tysabri, Part 2 - Ted Yednock

https://www.ibiology.org/human-disease/tysabri/#part-2

Overview
In the first of his two talks, Ted Yednock begins with an overview of multiple sclerosis. He describes how, in MS, immune cells are able to transverse the wall of blood vessels and infiltrate the brain and central nervous system resulting in damage to the myelin surrounding neurons. Yednock and his colleagues hypothesized that by blocking the infiltration of immune cells into the brain, the progression of the disease might be slowed. They went on to identify 4 integrin as the molecule that mediates adhesion of immune cells to the blood vessel wall, and they found that an 4 integrin antibody (Natalizumab or Tysabri) could block infiltration of the blood cells into the brain in a animal model of MS. Yednock then details the clinical development of Tysabri through to its approval by the FDA in 2004.
Just a few months after Tysabri was approved for MS treatment, two patients developed progressive multifocal leukoencephalopathy (PML), a fatal or seriously debilitating disease. In his second talk, Yednock describes the response of medical and regulatory groups and researchers to this discovery and its impact on the treatment of MS patients with Natalizumab/Tysabri.

About Ted Yednock
Dr. Yednock recently joined the Drug Advisory Board of the Myelin Repair Foundation, a nonprofit organization focused on the discovery and development of therapeutics for multiple sclerosis (MS). Previously Dr. Yednock was the Executive Vice President and Head of Global Research for Elan Pharmaceuticals and a scientist at Athena Neurosciences. Through his scientific work at Athena, Yednock invented Tysabri (Natalizumab), a monoclonal antibody therapeutic that was approved by the FDA, in 2004, for the treatment of MS. He continued to support the program from a scientific perspective as it moved through development for MS at Elan and later in collaboration with Biogen-Idec. In addition to his work with the Myelin Repair Foundation, Yednock is also a scientific advisor to several companies and start-ups.
Yednock was an undergraduate student at the University of Illinois, Champaign-Urbana. He received his PhD in anatomy and cell biology from the University of California, San Francisco where he was also a post-doctoral fellow.

Видео Bench to Bedside: Multiple Sclerosis and Tysabri, Part 2 - Ted Yednock канала iBiology